NCT01716403终止不适用
Influence of Telaprevir Exposure on the Severe Anemia Induced by Ribavirin/Pegylated Interferon/Telaprevir Tri-therapy in HCV Infected Patients
University Hospital, Grenoble1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2012年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- telaprevir concentration and area under the curve
研究概览
简要总结
The risk of severe anemia is increased in patients treated by tri-therapy compared to patients treated by bitherapy. The underlying mechanisms involved in this toxicity remain unexplored but could also depend on the global exposure of telaprevir. The trough concentration or AUC of telaprevir could therefore be a predictive factor of the onset of anemia in patients treated by ribavirin/PEG-INF/telaprevir. The early measurement of telaprevir and ribavirin concentrations could help to manage HCV tri-therapy to improve tolerance and SVR.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Man or woman older than 18 yr. 2- HCV genotype 1 infection as confirmed by a positive viral load 6 months after the selection visit or confirmed by the mean of a liver biopsy within 1 year before screening for the study.
- •3- Patient with one of the following criteria: Patient naive of any treatment against HCV infection Or Prior null responder patient: patient previously treated by ribavirin/PEG-INF for at least 12 weeks and whom HCV viral load decline was <2 log at week 12 Or Prior partial responder patient: patient previously treated by ribavirin/PEG-INF for at least 12 weeks, who never had a negative viral load while the viral load decline was >2 log at week 12 Or Prior relapser patient: patient previously treated by ribavirin/PEG-INF for 48 weeks, with a negative viral load at the end of treatment and a positive viral load 6 months later 4- Patient who has stopped his treatment for at least 12 weeks 5- Patient who had a liver biopsy or a Fibroscan within the 24 months before the start of the study with a Metavir fibrosis score F ≥
- •6- Patient who fulfills criteria for telaprevir treatment as defined by the licence 7- Patients who accepts to use 2 contraceptive methods until 6 months after the end of the treatment 8- Patient who had given his written informed consent 10- Patient insured under the french social security system
排除标准
- •1- Infection/co-infection by HCV genotype different than genotype 1 2- Patient with a medical contraindication to PEG-INF or ribavirin 3- Patient with history of allergy or intolerance to telaprevir 4- Patient using contraindicated drugs 5- Patient with history of decompensated liver disease and/or presenting biochemical measurements as follows at the inclusion visit:
- •International Normalized Ratio (INR) > 1,5
- •Albumin <3,3 g/dl
- •Total bilirubin>1,8 N apart for patient with Gilbert syndrome 6- Liver disease from other causes 7- Patient with hepatocellular carcinoma or history of cancer 8- Patient with a history of graft transplantation and treated by immunosuppressive drugs 9- Patient who are regularly treated by corticosteroids 11- Patient with hemophilia or coagulation troubles 12- HIV or HBV co-infection 14- Patient with body mass index> 30 kg/m2.
结局指标
主要结局
telaprevir concentration and area under the curve
时间窗: Day 0, Day 2, week 2, week 4, week 8 and week12
次要结局
- ribavirin concentration and area under the curve(Day 0, Day 2, week 2, week 4, week 8 and week12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effectiveness and safety of simeprevir-basd triple therapy for chronic hepatitis C in multicenter studyChronic hepatitis CJPRN-UMIN000014568The Kyushu Univerisity Liver Disease Study Group400
已完成
不适用
Ribavirin Bioavailability After Telaprevir ExposureHepatitis CNCT02881034Hospices Civils de Lyon37
已完成
不适用
The effect and safety in Telaprevir with combined peginterferon alpha-2b plus ribavirin for chronic hepatitis C patientsJPRN-UMIN000007071Department of Hepatology, Osaka City University , Graduate School of Medicine100
已完成
不适用
Telaprevir-based triple therapy significantly decreases the serum alpha-fetoprotein level in chronic hepatitis C patients: A prospective studyChronic hepatitis CJPRN-UMIN000013784Department of General Internal Medicine, Kyushu University Hospital200
进行中（未招募）
不适用
Study about human defence for chronic hepatitis C in patients who will be treated with telaprevir with peginterferon-alfa and ribaviriEUCTR2011-005636-26-NLFoundation for Liver Research25